KartogeninCat.Number：K8190Quantitysize:5mgTarget:TGF-beta/SmadPathway:StemCell/Wnt;TGF-beta/SmadSolubility:DMSO:≥42mg/mLBIOLOGICALACTIVITY:Kartogeninisaninducerofdifferentiationofhumanmesenchymalstemcellsintochondrocytes.InVitro:Kartogeninenhancescellproliferationinbothcelltypesinaconcentration-dependentmannerandinduceschondrogenicdifferentiationofstemcells,asdemonstratedbyhighexpressionlevelsofchondrogenicmarkersaggrecan,collagenIIandSox-9.Besides,kartogenininducestheformationofcartilage-liketissuesincellcultures,asobservedthroughthestainingofabundantproteoglycans,collagenIIandosteocalcin.Kartogeninstimulatestype-IcollagensynthesisoffibroblastsatthemRNAandproteinlevelsinatime-dependentmannerwithoutobviousinfluenceonfibroblasts’apoptosisandviability.Smad4/smad5oftheTGF-βsignalingpathwayisactivatedbykartogeninwhileMAPKsignalingpathwayremainsunchanged.KartogenintreatmentenhanceschondrocytepericellularmatrixassemblyandretentioninthepresenceofIL-1β.KartogeninpartiallyblockstheIL-1β-inducedincreasedexpressionofADAMTS-5.Additionally,kartogenin-treatedarticularchondrocytesexhibitsadecreaseinCD44proteolyticfragmentation.InVivo:heninjectedintointactratpatellartendons,kartogenininducescartilage-liketissueformationintheinjectedarea.WheninjectedintoexperimentallyinjuredratAchillesTBJs,woundhealingintheTBJsisenhanced,asevidencedbytheformationofextensivecartilage-liketissues.Kartogeninstimulatescollagensynthesisinthemousedermis.Dermisinthekartogenin(100nM)-treatedgroupexhibitsincreaseddermalthicknessandintensebluestaining,whichrepresentsmorecollagencompositioninthedermis.PROTOCOL(ExtractedfrompublishedpapersandOnlyforreference)CellAssay:RabbitBMSCsorPTSCsaretreatedwithvariousconcentrations(1nMto5μM)ofkartogenin.Themediumischangedevery3daysandafter2weeks,cellproliferationismeasuredbypopulationdoublingtime.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. 北京索莱宝科技有限公司是一家集研发、生产、销售、服务于一体的高科技生物企业。产品覆盖面广，品质可靠。先后开发了涵盖分子生物学、细胞生物学、免疫学、生物医学等领域的多种试剂及试剂盒。